Get the Stockscreener App
0.5899
3.06%
-0.0152
After Hours:
.57
-0.0199
-3.37%
Vincerx Pharma Inc stock is traded at $0.5899, with a volume of 289.93K.
It is down -3.06% in the last 24 hours and down -29.87% over the past month.
See More
Previous Close:
$0.6051
Open:
$0.629
24h Volume:
289.93K
Relative Volume:
0.30
Market Cap:
$3.17M
Revenue:
-
Net Income/Loss:
$-48.85M
P/E Ratio:
-0.2554
EPS:
-2.31
Net Cash Flow:
$-46.25M
1W Performance:
+10.80%
1M Performance:
-29.87%
6M Performance:
-95.80%
1Y Performance:
-99.47%
1-Day Range:
$0.52
$0.6667
1-Week Range:
$0.5135
$0.69
52-Week Range:
$0.4843
$113.40
Vincerx Pharma Inc Stock (VINC) Company Profile
Name
Vincerx Pharma Inc
Sector
Industry
Phone
650-800-6676
Address
260 SHERIDAN AVENUE, PALO ALTO
Compare VINC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.5899 | 3.17M | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline - Investing.com
VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline By Investing.com - Investing.com South Africa
Vincerx Pharma (VINC) Projected to Post Quarterly Earnings on Friday - Defense World
Vincerx Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vincerx Pharma Inc expected to post a loss of $3.40 a shareEarnings Preview - TradingView
Such Is The Power Of Vincerx Pharma Inc (NASDAQ: VINC) - Stocks Register
Vincerx Pharma plans reverse merger with QumulusAI By Investing.com - Investing.com Australia
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - GlobeNewswire
VINC stock touches 52-week low at $0.73 amid sharp annual decline - Investing.com UK
Vincerx Pharma Plans Reverse Merger With AI Infrastructure Firm QumulusAI -March 18, 2025 at 09:40 am EDT - Marketscreener.com
Vincerx Pharma plans reverse merger with QumulusAI - Investing.com India
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - Benzinga
Vincerx Pharma's $300M AI Transformation: QumulusAI Merger Creates New Computing Powerhouse - StockTitan
Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration - insights.citeline.com
Vincerx Pharma Plunges After Scrapping Reverse Merger With Oqory And Vivaso - Nasdaq
Vincerx Pharma terminates reverse merger term sheet and evaluates strategic alternatives - MSN
Vincerx Pharma Terminates Reverse Merger Deal With Oqory - MarketWatch
Vincerx Pharma Explores Strategic Alternatives Post Merger Termination - TipRanks
Vincerx Pharma Announces Termination Of Reverse Merger Term Sheet -February 28, 2025 at 04:12 pm EST - Marketscreener.com
Vincerx Pharma announces termination of reverse merger term sheet - TipRanks
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - The Manila Times
Vincerx Pharma, Inc. Terminates Reverse Merger Agreement and Will Explore Strategic Alternatives - Nasdaq
Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - StockTitan
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update - Defense World
VINC stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia
VINC stock touches 52-week low at $1.17 amid market challenges By Investing.com - Investing.com South Africa
Vincerx Pharma Regains Compliance With Nasdaq Listing Rule 5550(A)(2) -February 18, 2025 at 05:27 pm EST - Marketscreener.com
Vincerx Pharma announces reverse stock split; shares drop - MSN
VINC stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia
Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 1,022.5% - MarketBeat
VINC stock touches 52-week low at $1.62 amid market challenges - Investing.com Canada
Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258 - TipRanks
Vincerx Pharma and Oqory reveal merger and cancer drug data - Investing.com
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire
Vincerx Pharma and Oqory reveal merger and cancer drug data By Investing.com - Investing.com UK
Revolutionary Cancer Treatment Achieves Unprecedented 80% Success Rate in Clinical Trial - StockTitan
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Vincerx Pharma enters at-the-market equity offering deal - MSN
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Vincerx Pharma (NASDAQ:VINC) Stock Quotes, Forecast and News Summary - Benzinga
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Vincerx Pharma files for $100M mixed securities shelf - MSN
Vincerx Pharma (NASDAQ:VINC) Implements 1-for-20 Reverse Stock Split - Defense World
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma (VINC) Stock Price, News & Analysis - MarketBeat
Vincerx Pharma Inc Stock (VINC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):